Reliant Glycosciences LLC

Birmingham, AL

UEI
XZJ6B9Y31HX9
CAGE
7RGN5
Primary NAICS
325413 In-Vitro Diagnostic Substance Manufacturing
SAM.gov registration
Active through

Company facts

Self-certified in SAM.gov
  • Self Certified Small Disadvantaged Business
  • For Profit Organization
  • Limited Liability Company
Entity structure
Partnership or Limited Liability Partnership
SAM.gov registration date
Physical address
1716 Wingfield Cir, Birmingham, AL 35242, USA

Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .

Grant awards

Award Agency Obligated Awarded
Galnac-specific measurement of galactose-deficient IGA1 as a biomarker for IGA nephropathy R44DK139874 National Institute of Diabetes and Digestive and Kidney Diseases (NIH) $2,908,658
Utilizing IGG autoantibodies as biomarkers in IGA nephropathy R44DK126526 National Institute of Diabetes and Digestive and Kidney Diseases (NIH) $3,286,985
Utilizing IGG autoantibodies as biomarkers in IGA nephropathy R43DK126526 National Institute of Diabetes and Digestive and Kidney Diseases (NIH) $211,707

Similar vendors

Vendor Location Primary NAICS
Aptus Biosciences LLC UEI P69KB94KHH28 Gainesville, FL 541714 Research and Development in Biotechnology (except Nanobiotechnology)
Pgxl Technologies LLC UEI ZFN5J433DCT1 Louisville, KY 621511 Medical Laboratories
Vitan-Biotech LLC UEI ML5NLF9L1FP9 — 541714 Research and Development in Biotechnology (except Nanobiotechnology)
Attogene Corporation UEI M5VSPH6FK6D6 Austin, TX 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Discovery Life Sciences, LLC UEI GDJDUFGMSC14 Huntsville, AL 541714 Research and Development in Biotechnology (except Nanobiotechnology)

See more similar vendors on GovTribe

About the company

Written by GovTribe AI ·

Reliant Glycosciences LLC is a self-certified small disadvantaged business structured as a limited liability partnership, registered in SAM.gov since November 2016. The company specializes in developing clinical-grade diagnostic tests and biomarker assays, with a primary focus on medical research and diagnostic technology development. Its core expertise appears to be in creating advanced diagnostic tools for complex medical conditions, particularly in the realm of kidney and immunological diseases.

The company has received multiple federal grant awards from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), specifically focusing on developing diagnostic tests for IgA Nephropathy (IgAN). Its primary grant-funded projects involve creating clinical-grade assays to measure specific biomarkers, such as the GALD assay for detecting galactose-deficient IgA1 and an IgG autoantibody test. These projects aim to provide clinicians and researchers with improved methods for early disease detection, outcome prediction, and treatment monitoring. The grants, totaling approximately $1.9 million, support the company's work in transferring research technologies from academic settings (specifically the University of Alabama at Birmingham) into standardized, commercially viable diagnostic tools. The work involves detailed validation studies, prototype production, and initiating regulatory approval processes for these specialized medical diagnostic technologies.

Quick answers

Is Reliant Glycosciences LLC registered in SAM.gov?

Yes. Reliant Glycosciences LLC's SAM.gov registration is active through March 13, 2027.

What is Reliant Glycosciences LLC's most recent federal award?

Reliant Glycosciences LLC's most recent federal grant award is Galnac-specific measurement of galactose-deficient IGA1 as a biomarker for IGA nephropathy (R44DK139874), from National Institute of Diabetes and Digestive and Kidney Diseases (NIH), on June 20, 2024.

On GovTribe

See Reliant Glycosciences LLC's full federal record

  • Federal grant awards
  • Funding analysis by agency, NAICS and set-aside
  • Similar vendors
Try for free Login